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cationic, amphoteric or anionic branched polypeptides and a new conjugate containing a cationic
polypeptide carrier modiﬁed with a cell penetrating octaarginine. We investigated in vitro physiological
activity of these conjugates in several aspects: in vitro cytotoxicity and cytostatic effect, adhesion and cellular
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and on murine bone marrow derived macrophages. We found that these processes are dependent on the
properties of the carrier, on experimental conditions like concentration and incubation time. We found
that attachment of polypeptide and cell penetrating peptide to the bioactive agent, depending on the cell
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Delivery of daunomycin, a drug of anthracyclin family or its
conjugates into tumor cells and into macrophages that inﬁltrates the
tumor tissue couldbe apromisingapproachof tumor therapy.Despite its
high efﬁciency, daunomycin has numerous side effects such as vomiting,
hair loss and nausea. The drug also causes decreased with blood cell
count and has a marked cardiotoxic effect [1]. Coupling the drug to
macromolecular or peptide carrier could improve solubility, decrease
side effects and can offer the possibility of cell or tissue speciﬁc
introduction [2,3]. Surface receptors with conservative structure could
be targetedwith receptor speciﬁc carriers. Such receptors (e.g. scavenger
receptors) are expressed on macrophages and macrophage like tumor
cell lines like J774 [4]. Another approach for intracellulardelivery is using
cell penetrating peptides like oligoarginines with cationic character.
This method is less speciﬁc, though also could be highly efﬁcient
[5,6]. Polycationic macromolecular polypeptides are also promising
candidates for cell penetrating introduction [7]. These polypeptides are
proved to be taken up effectively by murine bone marrow derived
macrophages, although the mechanism of their uptake is presently not
precisely described [8]. Daunomycin-polypeptide conjugates were
tested earlier in our research group in vitro and in vivo on tumor cells
and on solid tumors. Daunomycin was coupled to polycationic poly[Lys
(Seri-dl-Alam)] (SAK) and to amphoteric poly[Lys(Glui-dl-Alam)] (EAK)
where m=2–3 and i~1.0 polypeptides via cis-aconitic acid spacer.The treatment with polycationic poly[Lys(cADj-Glui-dl-Alam)]) (cAD-
EAK), where m=2–3 and i and j~1.0 conjugate proved to be effective
in eliminating of immunosuppressive effect of daunomycin in mice
bearing tumor of L1210 origin [9]. Polypeptide-daunomycin conjugates
were also effective on multidrug resistant human leukemia (HL-60/
MDR1 and HL-60/MRP1) cell lines [10]. In the present work we carried
out systematic structure–function studies on the in vitro physiological
effect of cis-aconityl daunomycin conjugates containing polylysine
based polypeptide carrier. Four conjugates with polypeptide carrier
of different character were used: poly[Lys-(cADj-Glui-dl-Alam)], (cAD-
EAK); its succinylated polyanionic derivative, (poly[Lys-(cADj-SuccGlui-
dl-Alam)], (cAD-SuccEAK), poly[Lys-(cADj-Seri-dl-Alam)] (cAD-SAK) and
poly[Lys-(cADj-Seri-dl-Alam)]-Cys-Gly-Arg8, (cAD-SAK-Cys-Gly-Arg8),
a conjugate that contain a cell penetrating peptide, octaarginine. The
schematic structure of the conjugates is presented in Fig. 1. Here
we report on our ﬁndings concerning the in vitro cytotoxicity, adhesion
and in vitro cytostatic effect of the conjugates on murine bone marrow
derivedmacrophages (BMDM), onmurine (J774 and L1210) and human
(MonoMac6) tumor cell lines. We also describe the results of a detailed
study on the internalization of the conjugates. Data presented indicate
the inﬂuence of the carrier structure on theuptake of the drug-conjugate
and provided guideline for the identiﬁcation of structural elements
essential for the cellular uptake and for improved anti-tumor effect.
2. Materials and methods
2.1. Abbreviations
Abbreviations of amino acids and their derivatives follow the
revised recommendation of the IUPAC-IUB Committee on Biochemical
Fig. 1. Schematic presentation of daunomycin conjugates containing poly[L-Lys] based polypeptide carriers. A, poly[Lys-(cADi-Seri/Glui-dl-Alam)] (cAD-SAK/cAD-EAK). B, poly[Lys-
(cADj-Glui-dl-Alam)]-Cys-Gly-Arg8 (cAD-SAK-Cys-Gly-Arg8). C, poly[Lys-(cADj- SuccGlui-dl-Alam)] (cAD-SuccEAK).
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Acids and Peptides” (recommendations of 1983). Nomenclature of
branched chain polypeptides is used in accordance with the
recommended nomenclature of graft polymers [11]. For the sake of
brevity codes of branched chain polypeptides were constructed by
us using the one-letter codes of amino acids. All amino acids are
l conﬁguration unless otherwise stated. The other abbreviations in
this paper are the following: EDC: N-ethyl-N′-[3-(dimethylaminopro-
pyl)carbodiimide hydrochloride, MTT: 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide, TFA: triﬂuoroacetic acid, FBS: fetal
bovine serum, DMSO: dimethyl sulfoxide, TEA: triethylamine, DCM:
dichloromethane, NMM: N-methylmorpholine, PBS: phosphate-
buffered saline, Succ: succinyl, CF: 5(6)-carboxyﬂuorescein, rMu
M-CSF: recombinant murine macrophage colony stimulating factor.
2.2. Materials
Daunomycin hydrochloride was a gift from the Institute of Drug
Research Ltd. (Budapest, Hungary); cis-aconitic anhydride, EDC, MTT,
RPMI-1640 medium powder, glutamine, gentamycin, TFA and other
chemicals for buffers and eluents were from Sigma-Aldrich (Budapest,
Hungary). FBS was obtained from Gibco Brl. and from Sigma-Aldrich
(Budapest, Hungary). Dioxane, methanol, acetonitrile, DMSO, chloro-
form, and tetrahydrofuran were obtained from Molar Chemicals
(Budapest, Hungary). rMuM-CSF was from R&D Systems (Minneapolis,
MN, USA). Poly[Lys-(Ser0.9-dl-Ala2.5)], (SAK); poly[Lys-(Glu1.0-dl-
Ala2.3)], (EAK), were synthesized in our laboratory as described in
detail previously [12,13].
2.3. Synthesis of cAD-polypeptide conjugates
Cis aconityl daunomycin (cAD) was synthesized according to
Ryser and Shen [14] with modiﬁcations [15]. cAD was coupled to the
polypeptides using water-soluble carbodiimide EDC (1.5 eq.) as
coupling reagent. The conjugates were puriﬁed by gel permeation
chromatography. The conjugates were then freeze-dried and theywere dissolved in distilled water for the experiments. Daunomycin
content of the conjugates was determined by UV spectrophotometry.
2.4. Synthesis of cAD-SAK-Cys-Gly-Arg8
Cys-Gly-Arg8 peptide was synthesized by manual solid phase
synthesis on Rink-amide resin (0.335 g, 0.73 mmol/g) using Fmoc/
tBu strategy [16]. Coupling the Cys-Gly-Arg8 peptide to the cAD-
SAK conjugate was performed according to Bánóczi et al. [17]. First,
the free amino groups of the side chain terminating Ser was
chloroacetylated [18], then 1.2 eq. of Cys-Gly-Arg8 peptide was
added to the chloroacetylated conjugate in 0.1 M Tris–HCl (pH 8.2)
buffer. The conjugation was continued for 24 h at RT and ﬁnally
terminated by addition of an excess of Cys. The conjugate was puriﬁed
by dialysis against distilled water and then freeze-dried. The conju-
gate was characterized by amino acid analysis. Daunomycin content
was determined by UV spectrophotometry.
2.5. Succinylation of cAD-EAK
cAD-EAK (10 mg) was dissolved in carbonate buffer (0.5 M, pH
9.2) then 220 μL (220 μmol) succinic anhydride dissolved in DMSO
(c=100 μg/mL) was added with continuous stirring in 30 min at
room temperature; pH was adjusted between 9.0 and 9.2 with 0.1 M
NaOH. The reaction was continued for 4 h at RT. The product was
puriﬁed by gel permeation chromatography on PD10 column ﬁlled
with Sephadex G25 using distilled water as eluent and the column
was washed with 1% acetic acid (v/v).
2.6. Labeling of polymeric polypeptides with 5(6)-carboxyﬂuorescein
Polypeptides (10 mg) (6×10−7 to 1.9×10−7 mol)were dissolved in
2 mL sodium-carbonate buffer (0.1 M; pH9.4). 5(6)-carboxyﬂuorescein
succinimid ester was dissolved in DMF (c=10mg/mL, 0.21 mM) and
was added to the polypeptide solution in 20 μL aliquots. The reaction
was continued for 1 h at room temperature with continuous stirring.
Table 1
Chemical characteristics of daunomycin conjugates.
Conjugatea Polypeptide carrierb Dau [S%]c
cAD-SAK poly[Lys(Ser0.9-DL-Ala2.5)] 12.0
cAD-SAK-Cys-Gly-Arg8 poly[Lys(Ser0.8-DL-Ala2.4)] 11.0
cAD-EAK poly[Lys(Glu1.0-DL-Ala2.3)] 7.0
cAD-SuccEAK poly[Lys(Glu1.0-DL-Ala2.3)] 7.0
a Code of each branched chain polymeric polypeptide carrier is based on one-letter
symbol of amino acids.
b Amino acid composition was determined by amino acid analysis as after hydrolysis
in 6 M HCl at 105 °C for 24 h.
c Average degree of substitution for daunomycin was determined by UV
spectrophotometry.
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with Sephadex G25 using distilled water as eluent. The samples were
then freeze-dried and they were resolved in PBS (0.1 M, pH 7.4) before
use. Carboxyﬂuorescein content of the samples was determined by
RP-HPLC as described earlier [8].
2.7. Cell lines
Cell lines cells were maintained in RPMI 1640 medium containing
10% FCS, 2 mM L-glutamine and 0.16 mg/mL gentamycin in 5% CO2
atmosphere.
2.8. Isolation and culturing of bonemarrow culture-derivedmacrophages
(BMDM)
Bonemarrow cellswere isolated from the femur and tibia of female
Balb/c mice at 6–8 weeks of age. Cells were maintained in 10 cm
bacteriological Petri dishes in RPMI 1640 medium supplemented
with 10%FCS, 10 mM HEPES, 0.16 mg/mL gentamycin and 10 ng/mL
rMu M-CSF. The macrophages were harvested with PBS (0.1 M,
pH 7.4)+10 mM EDTA and plated on 24-well suspension culture
plates 24 h prior to the uptake assay or on 96 well tissue culture
plate 24 h before the cytotoxicity assay.
2.9. Measurement of cellular uptake by ﬂow cytometry
Twenty-four hours prior to the experiment cells were plated on 24
well plates for suspension cells. Cells were washed twice with FCS-
free RPMI medium before the treatment. The compounds to be tested
were added to the cells at 0.1, 1, 10, 50 and 100 μg/mL concentration,
and then incubated with the compounds for 0–60 min. After
washing twice with PBS (0.1 M; pH 7.4), cells were examined by
ﬂow cytometry (BD LSR II). Fluorescence intensity of coupled
daunomycin was recorded in case of cAD conjugates (λex=488 nm
and λem=571 nm) and ﬂuorescence intensity of CF was measured in
case of CF-SuccEAK (λex=488 nm and λem=519 nm) from 5000 to
10000 cells and ﬂuorescence mean was calculated. Assays were
performed in duplicates with two or three parallels in each assay.
Statistical analysis of data was performed by Student's t test at the
95% conﬁdence level.
2.10. Measurement of cytotoxicity and in vitro antitumor effect by MTT
assay
Cells were plated into 96 well tissue culture plate in culture
mediumwith initial cell number of 104 or 5×103 cells/well, 24 h prior
to the treatment. The compounds were added to the wells in serum
freemedium in 200 μL ﬁnal volume. After a 1.5 h incubation cells were
washed twice with serum free medium and in case of the cytostasis
assay fresh culture medium was added to each well and cells were
maintained at 37 °C for further 72 h. MTT (3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide) was added to each well at
0.36 mg/mL ﬁnal concentration. After 3.5 h incubation the absorbance
was measured with ELISA-reader (Labsystems MS Reader) at 540 and
620 nmas referencewavelength. Assayswere performed in duplicates
with two or four to six parallels in each assay. Statistical analysis of
data was performed by Student's t test at the 95% conﬁdence level.
Cytotoxic/cytostatic effect was calculated with the following Eq. (1):
Cytotoxicity= cytostasis %½  = 1−ODtreated =ODcontrolð Þ × 100 ð1Þ
2.11. Measurement of the adhesion of murine BMDM
Adhesion of murine bone marrow derived macrophages was
studied in xCELLigence instrument (Roche, Basel, Switzerland) thatmeasures electrical impedance by micro-electrodes integrated at
the bottom of each well of tissue culture E-Plates coated with
ﬁbronectin. First, baseline were recorded in culture medium (RPMI
1640 supplemented with 10% FCS, 2 mM L-glutamine and 0.16 mg/
mL gentamycin and 10 ng/mL M-CSF) as control and in separate wells
in the solution of the conjugates dissolved in culture medium
(c=100 μg/mL). After 1 h pre-incubation, 104 macrophages were
plated into each well. Adhesion was monitored for 48 h at 37 °C in
5% CO2 atmosphere. Cell index was calculated by the software of
xCELLigence instrument from electrical impedance data (Eq. (2))
Cell index = Zi−Z0ð Þ= 15; ð2Þ
Where Z0 is electrical impedance at 0 time point and Zi is electrical
impedance at i time point.
3. Results
3.1. Daunomycin conjugates
Three daunomycin conjugates containing cis-aconityl spacer (cA)
and polylysine based polycationic (poly[Lys-(cADi-Seri-dl-Alam)],
(cAD-SAK), amphoteric poly[Lys-(cADj-Glui-DL-Alam)], (cAD-EAK)
or anionic poly[Lys-(cADj-SuccGlui-DL-Alam)], (cAD-SuccEAK)) poly-
peptide carrier as well as a conjugate with additional Arg8 moiety
(cAD-SAK-Cys-Gly-Arg8) were used in these studies. The schematic
structure of these compounds is presented in Fig. 1, while their
chemical characteristics are summarized in Table 1.
3.2. In vitro cytotoxicity
Cytotoxicity of the cAD conjugates was tested at the concentration
range of 0.5–500 μg/mL calculated on the basis of its daunomycin
content by MTT assay. Results are expressed as a percentage of
untreated cells. Data are presented in Fig. 2. We found that cAD
conjugates were not toxic on BMDM,MonoMac6 and L1210 cells up to
c=500 μg/mL after 1.5 h treatment. J774 cells proved to be slightly
more sensitive to the treatment with the conjugates, but only at high
concentration (cN50 μg/mL) after 1.5 h incubation (37%).
3.3. Cellular uptake: Concentration dependence
Internalization of conjugates was examined under different
conditions using ﬂow cytometry. The inﬂuence of conjugate concen-
tration and temperature dependence was investigated on the uptake.
We also studied the involvement of scavenger receptor in the
internalization process using inhibition assays. The murine leukemia
cell lines (J774, MonoMac6 and L1210) as well as BMDM internalized
the cAD conjugates (Fig. 3) as well as HL-60 human leukemia cells
(data not shown). The uptake was concentration dependent. All
the conjugates were taken up the most efﬁciently by BMDM (from
Fig. 2. The effect of cAD conjugates on the viability of murine bone marrow derived macrophages (BMDM), murine and human leukemia cell lines. Diagrams represent the average
cytotoxicity of the conjugates as a percentage of untreated control±SD. Statistical analysis of data was performed by Student's t test. A, BMDM. B, J774. C, MonoMac6. D, L1210.
■, cAD-SAK; ●, cAD-EAK; ▲, cAD-SuccEAK; inserts: ◆, daunomycin.
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J774 cells internalized cAD-SuccEAK the most effectively, while L1210
cells and BMDM favored cAD-EAK (Fig. 3). The uptake of cAD-SAK-Fig. 3. Concentration dependence of the uptake of cAD conjugates after 60 min incubation. St
C, MonoMac6. D, L1210. ■, cAD-SAK; , cAD-EAK; □, cAD-SuccEAK.Cys-Gly-Arg8 conjugate was investigated on BMDM and HL-60 human
leukemia cells (Fig. 4). Results indicate that the internalization of
cAD-SAK-Cys-Gly-Arg8 by BMDM as well as by HL-60 cells wasatistical analysis of data was performed by Student's t test; *: pb0.05. A, BMDM. B, J774.
Fig. 4. Concentration dependence of the uptake of the cAD-SAK (■) and cAD-SAK-Cys-
Gly-Arg8 ( ) conjugates by BMDM (A) and HL-60 (B) cells after 60 min incubation.
Statistical analysis of data was performed by Student's t test; *: pb0.05.
Fig. 5. Uptake of cAD conjugates at 4 and 37 °C at c=100 μg/mL after 1 h. Columns
represent the average of mean ﬂuorescence values of a representative experiment
of two independent assays±SD after subtracting the control. A, BMDM. B, J774.
C, MonoMac6.■, 37 °C; , 4 °C. Statistical analysis of data was performed by Student's
t test; *: pb0.05.
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the conjugate more effectively over 10 μg/mL concentration than
murine bone marrow derived macrophages. The presence of the cell
penetrating peptide in the conjugate resulted in a marked increase in
the internalization: conjugate containing Arg8 was ingested even at
lower concentration (c=10 μg/mL) and more efﬁciently by both
cell types compared to the conjugate containing only the polycationic
polypeptide carrier.
3.4. Cellular uptake: Temperature dependence
The uptake of cAD-SAK, cAD-EAK and cAD-SuccEAK conjugates
was examined also at 4 °C versus 37 °C on BMDM, J774 and
MonoMac6 cells by ﬂow cytometry. In the case of both tumor
cell lines (J774 and MonoMac6) a substantial extracellular binding of
cAD-SAK could be observed (Fig. 5B and C). Nevertheless, a signiﬁcant
difference could be detected between the uptake at 37 °C and
extracellular binding at 4 °C of all the three conjugates studied.
3.5. The role of scavenger receptor A (SR-A) in the uptake
We examined the role of the scavenger receptor in the internal-
ization of cAD-EAK and cAD-SuccEAK conjugates by J774, (Fig. 6A and
B) and by BMDM (Fig. 6C and D). Uptake was inhibited either with the
SR ligand, sulphated polysaccharide fucoidan or poly(I) (Fig. 6) or a
SR-A speciﬁc monoclonal antibody 2F8. Inhibition of the uptake of
cAD-SuccEAK with poly(I) was compared to that of CF-SuccEAK. No
statistically signiﬁcant inhibition of the uptake of cAD-SuccEAK couldbe observed by fucoidan (c=100 μg/mL) or poly(I) (c=50 μg/mL) in
case of J774 cells. When blocking scavenger receptor with fucoidan in
case of bone marrow derived macrophages, we could observe only a
slight, though statistically signiﬁcant decrease in the uptake of cAD-
SuccEAK and a slight more pronounced effect when using poly(I)
as inhibitor (Fig. 6B and C). SR-A speciﬁc monoclonal antibody
also inhibited the internalization of cAD-SuccEAK (Fig. 7A) by BMDM.
The cargo (cAD vs. CF) coupled to the polypeptide carrier inﬂuenced
markedly the internalization via scavenger receptor by the macro-
phages (Fig. 7B). In case of CF-SuccEAK a more pronounced inhibition
of the uptake could be observed compared to cAD-SuccEAK
(inhibition=63% and 35%, respectively) when using poly(I) as
inhibitor (Fig. 7C–E).
3.6. Adhesion of BMDM
Adhesion of murine bone marrow derived macrophages was
studied on ﬁbronectin coated surface treated with all cAD conjugates
and daunomycin (as control) prior to the experiment. Results show
Fig. 6. Uptake of the conjugates after blocking scavenger receptor. Columns represent the average of mean ﬂuorescence values of a representative experiment of two independent
assays±SD after subtracting the control. A and B, J774. C andD, BMDM.■, uptake of the conjugates (c=100 μg/mL)without inhibitor; , uptake of the conjugates after pretreatment
with fucoidan (c=100 μg/mL);□, uptake of the conjugates after pretreatment with poly(I) (c=50 μg/mL). Statistical analysis of data was performed by Student's t test; *: pb0.05.
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could be explained with the cytotoxic effect of the drug on BMBM
cells. All four cAD-SAK, cAD-SAK-Cys-Gly-Arg8, cAD-EAK and cAD-
SuccEAK conjugates increased the adhesion of the macrophages.
The most adhesive compounds were cAD-EAK and cAD-SuccEAK
(Fig. 8A). In case of cAD-SAK a long-term cytotoxicity could be
detected, which resulted in the detachment of the macrophages afterFig. 7.Uptake of cAD-EAK and cAD-SuccEAK conjugates by BMDM after blocking class A scave
D, cAD-SuccEAK. E, CF-SuccEAK. Data were recorded by measuring 10000 cells and were ana
black lines represent uptake without inhibitor and grey lines represent uptake of the conju30 h. By contrast, cAD-SAK-Cys-Gly-Arg8 was not signiﬁcantly toxic
to the macrophages even after 50 h incubation (Fig. 8B).
3.7. In vitro antitumor effect of cAD conjugates
In vitro antitumor effect of the conjugates (cAD-SAK, cAD-EAK, and
cAD-SuccEAK) was studied on J774, MonoMac6 and L1210 cells bynger receptor withmAb 2F8. A, cAD-EAK. B, cAD-SuccEAK andwith poly(I). C, cAD-EAK.
lyzed by FACS DiVa software. Filled diagrams represent untreated control macrophages,
gate by BMDM in the presence of mAb 2F8.
Fig. 8. Adhesion of murine bone marrow derived macrophages on ﬁbronectin coated
(−) surface treated with daunomycin (---), cAD-SAK (-⋅-), cAD-EAK (⋅⋅⋅) and cAD-
SuccEAK (-⋅⋅-) (A) and cAD-SAK-Cys-Gly-Arg8 (⋅⋅⋅) (B), where cAD-SAK (---) was used
as control. Conjugate concentration was 100 μg/mL.
2215R. Szabó et al. / Biochimica et Biophysica Acta 1798 (2010) 2209–2216MTT assay. Results indicate that the conjugates inhibited only the
growth of J774 cells with similar efﬁcacy (cAD-SAK IC50=80.77±
0.57 μg/mL and cAD-SuccEAK: IC50=81.52±1.73 μg/mL, cAD-EAK:
IC50=62.38±13.5 μg/mL). In case of MonoMac6 cells, cAD-EAK
elicited only a slight inhibitory effect, but no IC50 values could be
calculated (Fig. 9).
4. Discussion
Anthracyclin type drug, daunomycin is applied mainly for therapy
of leukemia (e.g. acutemyeloid leukemia, acute lymphocytic leukemia
and chronic myelogenous leukemia), neuroblastoma and other typesFig. 9. In vitro antitumor effect of cAD conjugates on J774 (A), MonoMac6 (B) and L1210 (C) c
untreated control±SD. ■, cAD-SAK; ●, cAD-EAK; ▲, cAD-SuccEAK.of cancer. Daunomycin can inhibit division of tumor cells via inter-
calating DNA, stabilizing topoisomerase II–DNA complex or enhancing
the production of free radicals [19,20].
For the present studies, daunomycin was coupled to polylysine
based branched polypeptide carriers with different charge properties.
Biological properties of polymeric polypeptides based on poly[L-
lysine] were thoroughly investigated in our research group. In vitro
and in vivo cytotoxicity, immunogenicity, immunomodulatory effect,
biodistribution and blood survival have been studied [21]. It was
ascertained that the composition of the side chain and particularly
the character of the terminal amino acid signiﬁcantly inﬂuences the
biological properties including cellular uptake of the polypeptides
and even that of their conjugates with methotrexate [22], daunomy-
cin [2,23,24] and a GnRH antagonist peptide [25]. We have also
demonstrated that polylysine based branched polypeptides with
polyanionic character (SuccEAK and MalEAK) enter macrophages via
SR-A mediated endocytosis [26].
In this study four conjugates were used: a conjugate containing
amphoteric (cAD-EAK); anionic (cAD-SuccEAK) polypeptide carrier
and two polycationic conjugates without (cAD-SAK) or with cell
penetrating octaarginine (cAD-SAK-Cys-Gly-Arg8). Cytotoxicity and
cellular uptake were examined on murine bone marrow derived
macrophages and also on murine (J774 and L1210) and human
(MonoMac6) tumor cell lines. Two of these were macrophage like
cell lines J774 and MonoMac6). After 1.5 h incubation neither the
conjugates nor daunomycin were toxic on bone marrow derived
macrophages or on murine and human tumor cell lines.
The inﬂuence of the conjugates on the adhesion of bone marrow
derived macrophages was also investigated. The macrophages
attached to the surface coated with the conjugates the highest
adhesion was observes in case of the amphoteric cAD-EAK.
Two approaches of intracellular drug delivery of daunomycin are
discussed in this paper. We studied the inﬂuence of the polypeptide
carrier structure. First we analyzed the cell speciﬁc delivery of a cAD-
conjugate via scavenger receptor A, in which daunomycin was
coupled to a polypeptide carrier of polyanionic character. Inhibition
experiments were carried out in order to clarify if scavenger receptor
plays a role in the internalization of the polyanionic daunomycin
conjugate. SR inhibitors like the sulphated polysaccharide fucoidan
and a four-stranded nucleic acid, poly(I) were used. Class A scavenger
receptor was also blocked with a receptor speciﬁc monoclonal
antibody, 2F8 [27]. Our observations indicated that pretreatment
with the inhibitors resulted in a slightly reduced internalization of
succinylated cAD-conjugate, cAD-SuccEAK with polyanionic characterells. Diagrams represent the average cytostatic effect of the conjugates as a percentage of
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inhibition could be detected in case of J774 tumor cell line. As the
internalization of amphoteric cAD-EAK conjugate used as control was
essentially not altered by the SR inhibitors, we suppose that the
charge of the polypeptide carrier inﬂuences the mechanism of
internalization of the cAD conjugates. We can establish that SR-A
could play a role in the uptake of the polyanionic conjugate. Compared
the level of internalization of 5(6)-carboxyﬂuorescein labeled
SuccEAK (CF-SuccEAK) and cAD-SuccEAK we found CF-SuccEAK
more effective than the daunomycin containing conjugate. Based on
these results we can suppose that the cargo has a crucial inﬂuence on
the internalization process. The low effect of the scavenger receptor
inhibitors also points out that other mechanisms are also involved in
the internalization process of the polyanionic cAD-SuccEAK conjugate.
The secondway of intracellular delivery is cell penetration. It is known
that cationic oligopeptides like arginine rich peptides and 4- to 9-mer
oligoarginines enter the cells with high efﬁciency and they are able to
carry even a protein cargo into the cell [28–30]. Results showed that
cells internalized cAD-SAK-Cys-Gly-Arg8 at higher level than that of
conjugate cAD-SAK. This indicates that the presence of oligoarginine
in the conjugate has a marked inﬂuence on the uptake properties.
We also studied in vitro antitumor effect of cAD conjugates and we
found that their cytostatic effect was cell speciﬁc. Three conjugates
studied (cAD-SAK, cAD-EAK and cAD-SuccEAK) inhibited the growth
of J774 cells but had no antitumor effect on the other two cell lines
(MonoMac6 and L1210). In vitro antitumor effect of the conjugates
proved to be independent on the charge of the N-terminal amino acid
of the side chains of the carrier polypeptides.
Taken together, the cAD conjugates depending on their structure
are promising candidates for eliminating certain types of tumor cells
e.g. murine macrophage like cells.
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